Beta
Cinoxacin
medication Under reviewCinoxacin is a synthetic quinolone antibiotic administered orally for treating urinary tract infections. It is rapidly and almost completely absorbed, reaching peak serum concentrations within two hours, with about 60 to 70 percent protein binding. The drug achieves high urinary concentrations that persist above the minimal inhibitory levels for common gram-negative pathogens for up to 12 hours, with roughly 50 to 55 percent excreted unchanged in the urine. Cinoxacin works by binding strongly to bacterial DNA, interfering with RNA and protein synthesis, and inhibiting DNA gyrase, which prevents proper DNA replication and cell division. This mechanism targets susceptible urinary pathogens like Escherichia coli, Proteus species, Klebsiella, and Enterobacter. While primarily used for initial and recurrent urinary tract infections, its favorable pharmacokinetics support both treatment and low-dose prevention in adults.
Research summary
Scientific evidence from human pharmacokinetic studies demonstrates cinoxacin's effective absorption, distribution, and urinary excretion in healthy volunteers, supporting its role in achieving therapeutic levels against urinary pathogens. It is well-tolerated with low incidence of adverse effects and minimal development of resistance in fecal flora during extended dosing. No studies were identified evaluating benefits beyond antimicrobial activity in healthy humans.
No side effects tracked yet
No side effects have been reported by studies or users for this habit yet.
Research
No studies found yet. Request research to discover relevant studies.
Community updates
No updates yet for this supplement.
Be the first to share your experience!